Zhangzhou Pientzehuang Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Zhangzhou Pientzehuang Pharmaceutical Co Ltd cash flow-to-debt ratio. Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) has a Cash Flow-to-Debt Ratio of 0.05x as of September 2025, meaning its operating cash flow of CN¥117.38 Million could theoretically repay 0% of its total liabilities (CN¥2.44 Billion) in one year. Check cash flow reinvestment rate of Zhangzhou Pientzehuang Pharmaceutical Co to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (2001–2025)
Cash flow-to-debt ratio of Zhangzhou Pientzehuang Pharmaceutical Co Ltd from 2001 to 2025. Historical debt coverage capacity for Zhangzhou Pientzehuang Pharmaceutical Co Ltd across 25 annual periods. Check cash flow quality index of Zhangzhou Pientzehuang Pharmaceutical Co to evaluate the quality of earnings relative to operating cash generation.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2001–2025)
Zhangzhou Pientzehuang Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2001 to 2025. Year-by-year debt coverage analysis for Zhangzhou Pientzehuang Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Zhangzhou Pientzehuang Pharmaceutical Co cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.03x | CN¥77.03 Million | CN¥2.47 Billion | ▼ -93.6% |
| 2024 | 0.49x | CN¥1.31 Billion | CN¥2.70 Billion | ▼ -30.3% |
| 2023 | 0.70x | CN¥2.21 Billion | CN¥3.16 Billion | ▼ -71.8% |
| 2022 | 2.47x | CN¥6.87 Billion | CN¥2.78 Billion | ▲ +1161.5% |
| 2021 | 0.20x | CN¥462.27 Million | CN¥2.36 Billion | ▼ -74.0% |
| 2020 | 0.75x | CN¥1.47 Billion | CN¥1.95 Billion | ▲ +257.6% |
| 2019 | -0.48x | CN¥-879.37 Million | CN¥1.84 Billion | ▼ -205.3% |
| 2018 | 0.45x | CN¥612.31 Million | CN¥1.35 Billion | ▼ -18.1% |
| 2017 | 0.55x | CN¥676.93 Million | CN¥1.22 Billion | ▲ +80.6% |
| 2016 | 0.31x | CN¥394.54 Million | CN¥1.29 Billion | ▼ -24.6% |
| 2015 | 0.41x | CN¥305.51 Million | CN¥751.60 Million | ▲ +1.8% |
| 2014 | 0.40x | CN¥264.50 Million | CN¥662.34 Million | ▼ -2.9% |
| 2013 | 0.41x | CN¥274.34 Million | CN¥667.05 Million | ▲ +71.0% |
| 2012 | 0.24x | CN¥162.40 Million | CN¥675.22 Million | ▼ -60.8% |
| 2011 | 0.61x | CN¥232.95 Million | CN¥379.69 Million | ▲ +8.4% |
| 2010 | 0.57x | CN¥205.41 Million | CN¥362.97 Million | ▲ +86.7% |
| 2009 | 0.30x | CN¥129.52 Million | CN¥427.35 Million | ▲ +667.6% |
| 2008 | 0.04x | CN¥12.57 Million | CN¥318.45 Million | ▼ -86.1% |
| 2007 | 0.28x | CN¥60.04 Million | CN¥212.03 Million | ▼ -38.8% |
| 2006 | 0.46x | CN¥50.70 Million | CN¥109.53 Million | ▼ -42.6% |
| 2005 | 0.81x | CN¥69.06 Million | CN¥85.56 Million | ▼ -83.9% |
| 2004 | 5.01x | CN¥98.67 Million | CN¥19.69 Million | ▲ +541.1% |
| 2003 | 0.78x | CN¥32.36 Million | CN¥41.40 Million | ▲ +26.7% |
| 2002 | 0.62x | CN¥105.45 Million | CN¥170.99 Million | ▲ +16.5% |
| 2001 | 0.53x | CN¥65.84 Million | CN¥124.34 Million | — |